Centessa Pharmaceuticals plc
CNTA
$39.76
$0.060.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -79.24M | -66.16M | -54.89M | -50.34M | -26.14M |
| Total Depreciation and Amortization | 239.00K | -359.00K | 237.00K | 226.00K | 217.00K |
| Total Amortization of Deferred Charges | 345.00K | 879.00K | 271.00K | 293.00K | 312.00K |
| Total Other Non-Cash Items | 12.20M | 8.62M | 7.34M | 8.92M | 6.80M |
| Change in Net Operating Assets | -5.77M | 1.22M | -11.26M | 18.45M | -38.44M |
| Cash from Operations | -72.22M | -55.81M | -58.31M | -22.45M | -57.25M |
| Capital Expenditure | -- | -11.00K | -234.00K | -126.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.71M | -218.12M | 62.18M | -39.83M | -222.39M |
| Cash from Investing | 42.71M | -218.13M | 61.95M | -39.95M | -222.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 34.12M | 283.58M | 3.56M | 1.71M | 7.87M |
| Repurchase of Common Stock | -3.65M | -176.00K | -125.00K | -4.49M | -4.39M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -5.00K | 0.00 | 4.39M | -396.00K |
| Cash from Financing | 30.47M | 283.40M | 3.44M | 1.61M | 3.09M |
| Foreign Exchange rate Adjustments | 182.00K | 1.68M | -501.00K | -113.00K | -1.52M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.13M | 11.14M | 6.57M | -60.91M | -278.07M |